Barbara Eichhorst News Today

73% of patients with prior exposure to covalent BTK inhibitors responded

The combination of venetoclax and obinutuzumab with or without ibrutinib generated higher rates of undetectable minimal residual disease (MRD) and progression-free survival vs chemoimmunotherapy in fit patients with chronic lymphocytic leukemia.

A combination of venetoclax, ibrutinib, and obinutuzumab outperforms first-line chemoimmunotherapy for chronic lymphocytic leukemia in otherwise fit adults with few comorbidities.

Time-limited venetoclax, obinutuzumab and ibrutinib or venetoclax plus obinutuzumab prolonged PFS compared with chemoimmunotherapy among fit, previously untreated patients with chronic lymphocytic leukemia, according to study results.The preplanned interim analysis of the international, randomized phase 3 GAIA/CLL13 trial, presented during European Hematology Association Hybrid 2022 Congress,

Venetoclax/obinutuzumab as well as a triple combo with ibrutinib demonstrated better PFS in fit patients with CLL vs chemo, but higher rates of serious adverse events with ibrutinib remain a concern.